Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts
· seekingalpha.com
Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders. Learn why COAG stock is a buy.
I am bullish about Hemab Therapeutics ( COAG ) because I believe the company is being viewed far too narrowly (as just another newly public rare-disease biotech...